Gilead doubles down on Arcus
Will a TIGIT refocus see the stars finally align for the partners?
Merck’s latest move is in bispecifics
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
J&J deal cements Ambrx’s transformation
Ambrx’s PSMA-targeting ADC generated puzzling data at ESMO, but J&J has seen enough to launch a premium-priced buyout.
Merck KGaA takes a punt on Inspirna’s novel approach
The German group hopes to expand its colorectal cancer offering, taking on the only SLC6A8 inhibitor in development.
Astra scoops JP Morgan
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
